Login / Signup

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.

Paul EmerySarah HortonRaluca Bianca DumitruKamran NaraghiDésirée Mfm van der HeijdeRichard J WakefieldElizabeth M A HensorMaya H Buch
Published in: Annals of the rheumatic diseases (2020)
Compared with remission rates typically reported with first-line tumour necrosis factor inhabitor+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested. Trial registration number NCT02433184.
Keyphrases